{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["17(1)"],"submitter":["Gavila J"],"funding":["Instituto de Salud Carlos III","F. Hoffmann-La Roche","Save the mama","Pas a Pas","Teva Pharmaceutical Industries"],"journal":["BMC medicine"],"pagination":["8"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC6325829"],"repository":["biostudies-literature"],"pubmed_title":["Safety, activity, and molecular heterogeneity following neoadjuvant non-pegylated liposomal doxorubicin, paclitaxel, trastuzumab, and pertuzumab in HER2-positive breast cancer (Opti-HER HEART): an open-label, single-group, multicenter, phase 2 trial."],"pmcid":["PMC6325829"],"funding_grant_id":["Not applicable","PI16/00904"],"pubmed_authors":["Calvo I","Prat A","Virizuela JA","Gonzalez X","Gavila J","Llombart-Cussac A","Canes J","Andres R","Quero JC","Ciruelos E","Perez-Garcia J","Ruiz I","Martinez J","Oliveira M","Perello A","Munoz M","Morales S","Marin-Aguilera M","Pascual T","Martinez D","Pare L"],"additional_accession":[]},"is_claimable":false,"name":"Safety, activity, and molecular heterogeneity following neoadjuvant non-pegylated liposomal doxorubicin, paclitaxel, trastuzumab, and pertuzumab in HER2-positive breast cancer (Opti-HER HEART): an open-label, single-group, multicenter, phase 2 trial.","description":null,"dates":{"release":"2019-01-01T00:00:00Z","publication":"2019 Jan","modification":"2025-04-04T18:56:16.818Z","creation":"2025-04-04T18:56:16.818Z"},"accession":"S-EPMC6325829","cross_references":{"pubmed":["30621698"],"doi":["10.1186/s12916-018-1233-1"]}}